Lawrence and Isabel Barnett Drug Development 2027 Program Request for Applications

The aim of the Lawrence and Isabel Barnett Drug Development Program is to develop new treatments for ALS and seeks applications for the preclinical assessment of pre-investigational new drug (pre-IND) therapeutics for ALS that have a high probability of reaching the clinic within three years.

Funding: $250,000 per year

Duration: 2 years

Research Authority due date: 22.9.26

LOI (required) due date: 6.10.26

Full proposal due date: 8.12.26

Due to the IP and royalty clause in this RFA applicant must consult with RAMOT prior to submission of application.